Medicine for giving up drug

A drug and a new type of technology, applied in the fields of addiction medicine and neurobiology, can solve the problems of inability to forget the pleasure of drugs, lack of self-control in drug addiction, and achieve the effect of shortening the withdrawal time, low cost, and strong scientificity.

Inactive Publication Date: 2008-03-26
袁才尉
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pain brought by drugs to them is mainly divided into two parts. One is the withdrawal symptoms during the physiological withdrawal process. This process usually lasts for 10-15 days. Self-injury and self-mutilation behavior, in order to alleviate these pains, they relapse into drug use; the second is psychological withdrawal, they cannot forget the pleasure brought by drugs and lack the self-control of drug withdrawal, and desperately pursue that pleasure all their lives. This kind of madness doesn't work through education

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for giving up drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Select Amantadine Hydrochloride API, γ-aminobutyric acid A receptor (GABA A ) agonist indiplon (indiplon) raw material or and γ-aminobutyric acid B receptor (GABA B ) agonist baclofen (Beclofen) raw material, adopts conventional process to make preparation.

[0025] a. Amantadine Hydrochloride (Amantadine Hydrochloride) API 0.001% and γ-aminobutyric acid A receptor (GABA A ) agonist indiplon (indiplon) bulk drug 89.999%, auxiliary materials 10%, using conventional technology to make dosage forms such as tablets, capsules, granules.

[0026] Dosage: Three times a day, 1-2 capsules or one bag each time; 5 days is a course of treatment.

[0027] b. Amantadine Hydrochloride (Amantadine Hydrochloride) API 0.05% and γ-aminobutyric acid B receptor (GABA B ) agonist baclofen (Beclofen) bulk drug bulk drug 89.05%, auxiliary material is 10.9%, adopts conventional technology to make dosage forms such as tablet, capsule, granule.

[0028] Dosage: Three times a day, 1-2 capsules...

Embodiment 2

[0032]Select Benzhexol Hydrochloride (Benzhexol Hydrochloride) API, γ-aminobutyric acid A receptor (GABA A ) agonist Zolpidem (Zolpidem) API or and γ-aminobutyric acid B receptor (GABA B ) agonist gabapentin (Gabapentin) bulk drug, which is made into preparations by conventional techniques.

[0033] a. Benzhexol Hydrochloride (Benzhexol Hydrochloride) API 1% and γ-aminobutyric acid A receptor (GABA A ) agonist Zolpidem (Zolpidem) bulk drug 80%, auxiliary materials 19%, adopt conventional technology to make dosage forms such as powder, drop pill, micropill.

[0034] Dosage: Three times a day, one bag or 10 capsules each time; 5 days is a course of treatment.

[0035] b. Benzhexol Hydrochloride (Benzhexol Hydrochloride) API 2% and γ-aminobutyric acid B receptor (GABA B ) agonist gabapentin (Gabapentin) crude drug 70%, auxiliary material is 28%, adopts conventional technology to make dosage forms such as powder, dripping pill, micropill.

[0036] Dosage: Three times a day, on...

Embodiment 3

[0040] Select benserazide hydrochloride (Benserazide Hydrochloride) API, γ-aminobutyric acid A receptor (GABA A ) agonist topiramate (topiramate) API or and γ-aminobutyric acid B receptor (GABA B ) agonist pregabalin (Pregabalin) bulk drug, which is made into preparations by conventional techniques.

[0041] a. Benserazide Hydrochloride (Benserazide Hydrochloride) raw material 5%, γ-aminobutyric acid A receptor (GABA A ) agonist topiramate (topiramate) raw material drug 65%, auxiliary material 30%, adopt conventional technology to make solution, syrup, emulsion, suspension.

[0042] Dosage: three times a day, one bottle at a time; 5 days is a course of treatment.

[0043] b. Benserazide Hydrochloride (Benserazide Hydrochloride) raw material 10%, γ-aminobutyric acid B receptor (GABA B ) agonist Pregabalin (Pregabalin) raw material drug 75%, auxiliary material 15%, adopt conventional technology to make solution, syrup, emulsion, suspension.

[0044] Dosage: three times a day...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a new-type drug-stopping medicine. Its raw material composition includes (by wt%) 0.01%-30% of amantadine hydrochloride or trihexyphenidyl hydrochloride or benserazide hydrochloride or memantine bydrochloride, 99.009%-65% of gamma-aminobutyric acid A receptor agonist raw material medicine or/and gamma-aminobutyric acid B receptor agonist raw material medicine, and the rest is auxiliary material. Said drug-stopping medicine can be made into various conventional dosage forms of tablet, capsule, granules, power, dripping pills and others.

Description

Technical field: [0001] The invention relates to a novel detoxification drug, which belongs to the technical fields of addiction medicine and neurobiology. Background technique: [0002] my country currently has more than 1.17 million registered drug addicts. According to the 1:10 ratio of registered drug addicts to drug addicts recommended by the United Nations anti-drug agency, there are 11 million potential drug addicts in my country. The existence of this special group seriously threatens the social stability and sustainable development of our country. The drug problem has become a national construction The main threat to a harmonious society. In order to win the fight against drug addiction, we must rely on biomedical technology for drug addiction withdrawal. Strengthening the pace of R&D and application in this technology field plays an important role in achieving breakthroughs in drug control work. [0003] At present, all countries in the world attach great importan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4453A61K31/519A61K45/06A61P25/36A61K31/13A61K31/175A61K31/195A61K31/357A61K31/437
Inventor 刘正琴
Owner 袁才尉
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap